

March 16, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**SymBio Secures Japan Patent
for Use of IV BCV in Malignant Lymphoma
— Accelerating Expansion into Oncology —**

Tokyo, Japan, March 16, 2026 – SymBio Pharmaceuticals Limited (hereinafter “SymBio” or the “Company”) today announced that the Japan Patent Office has granted a patent covering the use of intravenous brincidofovir (IV BCV) for the treatment of malignant lymphoma.

The patent is based on findings generated through collaborative research with the National Cancer Centre Singapore. As part of SymBio’s commitment to rare diseases, the Company has been conducting research targeting malignant lymphomas, including rare histological subtypes. Through this collaboration, SymBio has scientifically demonstrated that BCV, which has principally been developed for the treatment of viral infections following hematopoietic stem cell transplantation (HSCT), exhibits antitumor effects against malignant lymphomas including NK/T-cell lymphoma and B-cell lymphoma.

This patent secures SymBio’s exclusive rights to the use of IV BCV in hematologic malignancies in Japan. The Company submitted the corresponding Patent Cooperation Treaty (PCT) application on August 30, 2023, and continues to strengthen its global intellectual property portfolio for IV BCV.

In addition to hematologic malignancies, SymBio is pursuing patent applications in solid tumor indications based on preclinical study results. The Company will explore clinical development opportunities across multiple cancer types, including malignant lymphoma.

SymBio is currently advancing a Phase 3 clinical trial for adenovirus infection following HSCT, and a Phase 2 clinical trial for progressive multifocal leukoencephalopathy (PML) in the neurodegenerative disease area. This patent registration strengthens the foundation for SymBio’s expansion into the oncology field,

complementing the Company's existing development programs.

In the oncology field, SymBio is collaborating with world-class research institutions including the National Cancer Centre Singapore, the Brain Tumor Center at the University of California, San Francisco, and the Gustave Roussy Institute in France. The Company will continue to accumulate insights through these collaborations and advance research and development in oncology.

Statement from Fuminori Yoshida, President and CEO: “This patent represents a significant advancement of SymBio’s three-pillar strategy spanning post-transplant viral infections, neurodegenerative diseases, and oncology. We remain committed to strengthening our research and development capabilities and intellectual property portfolio.”

This event is not expected to have a material impact on the Company’s consolidated financial results for the fiscal year ending December 2026.

Notes

Summary of Use Patent for IV BCV in Malignant Lymphoma

- Patent Number: 7827310
- Patent holder: SymBio Pharmaceuticals Limited
- Term of Validity: August 30, 2043
- Scope: Use of BCV for the Treatment of Malignant Lymphoma

BCV Business Strategy Based on Three Therapeutic Pillars

Since obtaining the global license for BCV in September 2019, SymBio has advanced collaborative research with world-class institutions to unlock IV BCV’s potential across three strategic therapeutic areas where the Company is currently focusing its development resources: (1) viral infections following hematopoietic stem cell transplantation; (2) hematologic and solid tumors; and (3) neurodegenerative diseases.